8-KMaterial AgreementsSecurities & ListingExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Oct 12, 2005)

Filed October 12, 2005For Securities:ALNY

Summary

On October 12, 2005, Alnylam Pharmaceuticals, Inc. (ALNY) announced the closing of a significant transaction with Novartis Pharma AG. Alnylam issued and sold approximately $58.5 million worth of common stock to Novartis, consisting of 5,267,865 shares at $11.11 per share. This equity issuance was completed under a Stock Purchase Agreement dated September 6, 2005. In conjunction with the stock purchase, an Investor Rights Agreement became effective, and Alnylam entered into a Research Collaboration and License Agreement with Novartis Institutes for BioMedical Research, Inc. These agreements were previously outlined in a September filing, and this 8-K filing confirms the closing of the stock sale and the execution of the collaboration. The sale of shares to Novartis was conducted under Section 4(2) of the Securities Act of 1933, exempting it from public offering registration requirements, with Novartis acquiring the shares for investment purposes.

Key Highlights

  • 1Alnylam Pharmaceuticals closed a stock purchase agreement with Novartis Pharma AG on October 12, 2005.
  • 2Novartis purchased 5,267,865 shares of Alnylam common stock for approximately $58.5 million.
  • 3The per-share purchase price for Alnylam's common stock was $11.11.
  • 4An Investor Rights Agreement between Alnylam and Novartis became effective at the closing.
  • 5Alnylam entered into a Research Collaboration and License Agreement with Novartis Institutes for BioMedical Research, Inc.
  • 6The equity sale to Novartis was made in reliance on the Section 4(2) exemption for unregistered securities.
  • 7Novartis represented its intent to acquire the shares for investment and not for distribution.

Frequently Asked Questions

Alnylam received approximately $58.5 million in gross proceeds from the sale of its common stock to Novartis. This infusion of capital is significant for a company of its size and stage, likely bolstering its financial resources for research and development.

The agreement involves both a strategic equity investment by Novartis in Alnylam and a research collaboration and license agreement. This suggests a potential partnership where Novartis is supporting Alnylam's pipeline while also gaining rights to certain research or technology.

The shares were issued and sold to Novartis in reliance on the Section 4(2) exemption from the registration requirements of the Securities Act of 1933. This exemption is typically available for private placements not involving a public offering, and it requires that the purchaser (Novartis) is sophisticated, capable of bearing investment risk, and acquiring the shares for investment purposes, not for immediate resale.

The filing doesn't detail the specific terms of the Research Collaboration and License Agreement beyond stating its existence and that it was contemplated by the Stock Purchase Agreement. Investors would need to refer to the referenced exhibits (though not provided here) or future Alnylam disclosures for details on the scope of the collaboration and any licensing rights granted to Novartis.